Peter Joosten

1.1k total citations
18 papers, 527 citations indexed

About

Peter Joosten is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Peter Joosten has authored 18 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 8 papers in Oncology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Peter Joosten's work include Lymphoma Diagnosis and Treatment (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Cancer Treatment and Pharmacology (4 papers). Peter Joosten is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Cancer Treatment and Pharmacology (4 papers). Peter Joosten collaborates with scholars based in Netherlands, Austria and Switzerland. Peter Joosten's co-authors include Hanneke C. Kluin‐Nelemans, Willem E. Fibbe, J. E. Landegent, J.H. Frederik Falkenburg, Ellie G.A. Lurvink, Roel Willemze, Cornelis A.M. van Bergen, Petra Kluck, Willem M. Smit and Amon R. Wafelman and has published in prestigious journals such as Blood, European Journal of Cancer and British Journal of Haematology.

In The Last Decade

Peter Joosten

18 papers receiving 511 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Joosten Netherlands 10 227 212 180 155 110 18 527
Laura Bellio Italy 10 186 0.8× 203 1.0× 142 0.8× 102 0.7× 82 0.7× 15 508
Kahaku Emoto Japan 6 182 0.8× 293 1.4× 167 0.9× 83 0.5× 194 1.8× 9 827
Liliana Morales Argentina 2 144 0.6× 236 1.1× 134 0.7× 69 0.4× 141 1.3× 2 625
Siba El Hussein United States 13 160 0.7× 125 0.6× 97 0.5× 178 1.1× 111 1.0× 67 511
Gi June Min South Korea 13 176 0.8× 352 1.7× 78 0.4× 108 0.7× 92 0.8× 97 552
Neal P. Christiansen United States 14 158 0.7× 158 0.7× 99 0.6× 62 0.4× 47 0.4× 32 474
Scott Marshall United Kingdom 11 135 0.6× 141 0.7× 161 0.9× 71 0.5× 84 0.8× 32 468
M. Hensel Germany 10 216 1.0× 241 1.1× 110 0.6× 257 1.7× 253 2.3× 25 564
J.M. Kremer United States 10 54 0.2× 269 1.3× 194 1.1× 77 0.5× 169 1.5× 27 798
Maciej Kaźmierczak Poland 13 90 0.4× 194 0.9× 63 0.3× 102 0.7× 93 0.8× 41 475

Countries citing papers authored by Peter Joosten

Since Specialization
Citations

This map shows the geographic impact of Peter Joosten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Joosten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Joosten more than expected).

Fields of papers citing papers by Peter Joosten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Joosten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Joosten. The network helps show where Peter Joosten may publish in the future.

Co-authorship network of co-authors of Peter Joosten

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Joosten. A scholar is included among the top collaborators of Peter Joosten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Joosten. Peter Joosten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Roon, Eric N. van, Peter Joosten, Robby E. Kibbelaar, et al.. (2017). The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study. European Journal of Clinical Pharmacology. 73(6). 771–778. 5 indexed citations
2.
Kibbelaar, Robby E., J.W.W. Coebergh, Nic J.G.M. Veeger, et al.. (2017). Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: A case study in haemato-oncology. European Journal of Cancer. 86. 178–185. 31 indexed citations
3.
Nijland, Marcel, Gustaaf van Imhoff, Peter Joosten, et al.. (2017). Relapse in stage I(E) diffuse large B‐cell lymphoma. Hematological Oncology. 36(2). 416–421. 9 indexed citations
4.
Schaafsma, Martyn Ronald, Peter Joosten, E.F.M. Posthuma, et al.. (2015). Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study. Quality of Life Research. 24(12). 2895–2906. 36 indexed citations
5.
Blommestein, Hedwig M., Djamila E. Issa, Peter Joosten, et al.. (2014). Cost‐effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population‐based study. European Journal Of Haematology. 92(5). 398–406. 17 indexed citations
6.
Hoogendoorn, Mels, Peter Joosten, Huib Storm, et al.. (2014). Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. British Journal of Haematology. 165(4). 489–496. 68 indexed citations
7.
Roon, Eric N. van, Peter Joosten, Robby E. Kibbelaar, et al.. (2014). Overall Survival Patterns in Patients with Multiple Myeloma in the Era of Novel Agents and the Role of Initial Clinical Presentation and Comorbidities: A Population-Based Study. Blood. 124(21). 2136–2136. 1 indexed citations
8.
9.
Lokhorst, Henk M., Bronno van der Holt, Sonja Zweegman, et al.. (2013). Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial. Blood. 122(21). 3332–3332. 1 indexed citations
10.
Schaafsma, M. Ronald, Okke de Weerdt, Peter Joosten, et al.. (2013). Real-world costs of chronic lymphocytic leukaemia in the Netherlands. Leukemia Research. 38(1). 84–90. 8 indexed citations
11.
12.
Joosten, Peter, Mels Hoogendoorn, Huib Storm, & Robby E. Kibbelaar. (2006). HemoBase: A Multidisciplinary Registration Systeem in Hemato-Oncology.. Blood. 108(11). 5506–5506. 2 indexed citations
13.
Hovenga, Sjoerd, H. de Graaf, Peter Joosten, et al.. (2003). Enteropathy-associated T-cell lymphoma presenting with eosinophilia.. PubMed. 61(1). 25–7. 7 indexed citations
14.
Bakker, A., et al.. (2003). Adequate Sampling in Cryoglobulinaemia: Recommended Warmly. Clinical Chemistry and Laboratory Medicine (CCLM). 41(1). 85–9. 17 indexed citations
15.
16.
Falkenburg, J.H. Frederik, Amon R. Wafelman, Peter Joosten, et al.. (1999). Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. Blood. 94(4). 1201–1208. 13 indexed citations
17.
Falkenburg, J.H. Frederik, Amon R. Wafelman, Peter Joosten, et al.. (1999). Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. Blood. 94(4). 1201–1208. 224 indexed citations
18.
Joosten, Peter, et al.. (1995). Pancytopenia related eosinophilia in rheumatoid arthritis: a specific methotrexate phenomenon?. PubMed. 22(7). 1373–6. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Bellio Breakdown of academic impact, for papers by Kahaku Emoto Breakdown of academic impact, for papers by Liliana Morales Breakdown of academic impact, for papers by Siba El Hussein Breakdown of academic impact, for papers by Gi June Min Breakdown of academic impact, for papers by Neal P. Christiansen Breakdown of academic impact, for papers by Scott Marshall Breakdown of academic impact, for papers by M. Hensel Breakdown of academic impact, for papers by J.M. Kremer Breakdown of academic impact, for papers by Maciej Kaźmierczak
Rankless by CCL
2026